Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis - Scorecard - MDSpire
Advertisement
Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis
Clinical Scorecard: Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Infection-associated cancers in immunocompromised populations
Key Mechanisms
T-cell immunodeficiencies leading to viral infections and tumorigenesis
Target Population
Solid organ transplant recipients, hematopoietic stem cell transplant recipients, people living with HIV or AIDS
Care Setting
Oncology and transplant medicine
Key Highlights
Immunocompromised individuals have a distinct cancer profile with high-risk malignancies.
Infection-related cancers account for 13% of all cancer incidences globally.
Tumor mutational burden (TMB) is a potential biomarker for predicting responses to immunotherapy.
Opportunistic infections significantly contribute to morbidity and mortality in these populations.
Current therapeutic strategies for cancer in immunocompromised patients lack consensus.
Guideline-Based Recommendations
Diagnosis
Assess cancer risk in immunocompromised patients through population-based cohort studies.
Management
Consider the implications of TMB when evaluating immunotherapy options.
Monitoring & Follow-up
Regularly monitor for opportunistic infections and cancer development in at-risk populations.
Risks
High-risk cancers are more prevalent in immunocompromised individuals due to impaired immune surveillance.
Patient & Prescribing Data
Immunocompromised individuals including SOT and HSCT recipients, and PLHIV
Checkpoint inhibitors may offer survival benefits but require careful consideration due to immune suppression.
Clinical Best Practices
Implement targeted prevention strategies for infection-related cancers.
Utilize TMB as a biomarker for immunogenicity in treatment planning.
Conduct comprehensive studies to better understand cancer burden in immunocompromised populations.
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 16 - 31.
